DRD2 and amyotrophic lateral sclerosis: Previously, we evaluated the efficacy of FDA-approved drugs using motor neurons that were derived from ALS patient-derived iPSCs and found ropinirole, which is a dopamine D2 receptor agonist to treat Parkinson’s disease, to be a promising therapeutic compound [17].